Trials / Completed
CompletedNCT02046564
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 412 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASC-01 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2014-01-28
- Last updated
- 2018-05-21
- Results posted
- 2018-05-21
Locations
29 sites across 5 countries: Australia, Japan, Malaysia, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT02046564. Inclusion in this directory is not an endorsement.